Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexofenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | DRD3 | P35462 | 3/20 | 0.98 |
| ▸ | DRD2 | P14416 | 2/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.96 |
| ▸ | HTR2A | P28223 | 2/20 | 0.96 |
| ▸ | HTR2B | P41595 | 2/20 | 0.96 |
| ▸ | BLM | P54132 | 2/20 | 0.96 |
| ▸ | CNR1 | P21554 | 1/20 | 0.96 |
| ▸ | APEX1 | P27695 | 1/20 | 0.96 |
| ▸ | PDE4A | P27815 | 1/20 | 0.96 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.96 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.77 |
| ▸ | GMNN | O75496 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexofenadine SCHEMBL29562068 | 0.99 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL40914 | 0.99 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL40915 | 0.99 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL1395627 | 0.98 | HRH1 (0.98) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL48729 | 0.98 | HRH1 (0.98) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL1972366 | 0.98 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL1561082 | 0.98 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL3178320 | 0.98 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL4901 | 0.98 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL7104316 | 0.98 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671071-B2 | Polymorphic Form XVI of fexofenadine hydrochloride | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-02 | — | — | US | disclosed |
| US-20090054486-A1 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE | TEVA PHARMACEUTICALS USA, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20060217557-A1 | Polymorphic form XVI of fexofenadine hydrochloride | KROCHMAL BARNABA | 2006-09-28 | — | — | US | disclosed |
| EP-1474392-A1 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003104197-A9 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE | TEVA PHARMA (IL) | 2004-05-27 | — | — | WO | disclosed |
| US-20040044038-A1 | Polymorphic form XVI of fexofenadine hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003104197-A1 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044038-A1 | Polymorphic form XVI of fexofenadine hydrochloride | UBE2V1, XDH, F5 | HRH1 67/4885LMNA 3538/4885DRD3 1635/4885 |
| US-20090054486-A1 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE | UBE2V1, XDH, F5 | HRH1 67/4885LMNA 3538/4885DRD3 1635/4885 |
| US-20060217557-A1 | Polymorphic form XVI of fexofenadine hydrochloride | UBE2V1, XDH, F5 | HRH1 67/4885LMNA 3538/4885DRD3 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.